The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Splicing modulator H3B-8800 in myeloid malignancies: phase 1 results
David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a clinical trial of H3B-8800, a splicing modulator, in myeloid cancers (NCT02841540). This phase I, open-label, first-in-human study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of H3B-8800 in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
